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Background: Benefits of sutureless and rapid deployment (SURD) bioprostheses in bicuspid aortic valves 
(BAV) are controversial. The aim of this study is to report the outcomes of patients undergoing aortic 
valve replacement (AVR) for BAV from the Sutureless and Rapid-Deployment Aortic Valve Replacement 
International Registry (SURD-IR).
Methods: Of the 4,636 patients who received primary isolated SURD-AVR between 2007 and 2018, 191 
(4.1%) BAV patients underwent AVR with SURD valve. 
Results: Overall 30-day mortality was 1.6%. The Intuity valve was implanted in 53.9% of cases, whereas 
the Perceval was implanted in 46.1%. Rate of stroke for isolated AVR was 4.2%. No case of endocarditis, 
thromboembolism, myocardial infarction, valve dislocation or structural valve deterioration was reported in 
the early phase. Rate of pacemaker implantation and moderate-severe aortic regurgitation (AR) were 7.9% 
and 3.7%, respectively. 
Conclusions: BAV is not considered a contraindication for the implantation of SURD valves. However, 
detailed information of aortic root geometry as well as the knowledge of some technical considerations are 
mandatory for a good outcome.
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Introduction
Bicuspid aortic valve (BAV) is a common congenital 
defect which occurs in 1–2% of the general population. 
BAV is composed of two instead of three leaflets, and 
often associated with one raphe in one cusp. The most 
common morphology is the type 1 according to the 
Sievers classification (1). These leaflet alterations often 
induce progressive fibrocalcific stenosis requiring surgery. 
Interestingly, it has been estimated that more than 50% of 
all aortic valve replacements (AVR) for aortic stenosis are 
related to BAV (2). 
Sutureless and rapid deployment (SURD) valves 
represent an excellent treatment option for surgical AVR, 
as they simplify the surgical procedure and reduce operative 
times (3-7). However, in the setting of BAV, these benefits 
are less clear. Despite several studies demonstrating good 
clinical outcomes, some reports suggest that SURD valves 
may increase the risk of paravalvular regurgitation and/or 
potential dislocation related to BAV aortic root asymmetry 
(8-12). Therefore, the aim of our study is to report the 
outcomes of patients undergoing AVR with SURD valves 
in patients with BAV from the Sutureless and Rapid-
Deployment Aortic Valve Replacement International 
Registry (SURD-IR). 
Methods 
SURD-IR
The SURD-IR was established in 2015, enrolling patients 
at eighteen cardiac centres in Europe, Australia, and 
Canada. The study population was defined as patients 
undergoing SURD-AVR intervention using any available 
sutureless and rapid-deployment valve prosthesis either by 
conventional sternotomy or a less invasive approach. Valve 
prosthesis types included Perceval (Livanova PLC, London, 
UK) EDWARDS INTUITY/INTUITY Elite (Edwards 
Lifesciences, Irvine, CA, USA) and Enable 3F (Medtronic, 
MN, USA). AVR was performed via full sternotomy, 
ministernotomy and minithoracotomy. Details of the site 
selection and invitation as well as endpoints have been 
previously reported (5). Briefly, centers that had published 
reports on more than 50 SURD-AVR cases were initially 
invited to participate in the present database, as this was 
hypothesized to represent experienced centers with quality 
data collection. Further institutions recommended by the 
IVSSG Research Steering Committee were also invited to 
participate in the retrospective registry. Ethics approval was 
obtained at each of the participating centers, and datasets 
were submitted according to predefined spreadsheet 
format. Participating SURD-IR centers enrolled between 
40 and 735 patients and collected information on 
demographics, patient comorbidities, functional status, 
imaging studies, surgical data, postoperative course, clinical 
and hemodynamic outcomes. Following electronic data 
submission, each dataset was evaluated to ensure that 
all patients were older than eighteen years. All variables 
between datasets were assessed with identical variables 
collated into a centralized database. Isolated variables 
reported by less than 25% of centers were excluded from 
analysis. Individually missing data and centre-specific non-
reported data were coded separately. Clinically important 
absent data were queried with the submitting centre. Data 
were analyzed for clinical face validity and internal validity. 
Submitted clinical data were compared against published 
data for inconsistencies. 
Patients selection
We examined 4,636 patients enrolled in the registry between 
April 2007 and December 2019. Exclusion criteria were 
tricuspid aortic valve, reoperative AVR and implantation of 
the off-market Enable 3F valve. The final sample included 
191 patients with BAV who underwent AVR. 
Statistical analysis
Continuous data were expressed as mean ± standard 
deviation and categorical variables as percentages. The 
Kolmogorov-Smirnov test was used to check for normality 
of data. Where continuous variables did not follow a normal 
distribution, the median and interquartile range were 
reported. 
Results 
Of the 4,636 patients who underwent AVR between 2007 
and 2019, a total of 191 patients with BAV (4.1%) received 
SURD valves. Baseline characteristics are reported in 
Table 1. There were 92 (48.2%) male patients and overall 
mean age was 70.7±9.8 with a median EuroSCORE I and 
II of 5.8% (3.3–8.7%) and 1.6% (1–2.6%), respectively. 
The indication for AVR was aortic stenosis in 56% of the 
patients, mixed disease in 43.5% and regurgitation in 0.5%. 
Mean LVEF was 57.8%±9.9% and 3 patients presented 
with LVEF <30%. 
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Surgical procedure
Operative data are reported in Table 2. The majority of 
patients underwent a minimally invasive approach (73.8%). 
Specifically, ministernotomy was performed in 47.6% of 
procedures, followed by right anterior minithoracotomy 
(26.2%) and full sternotomy (26.2%). Associated procedures 
included coronary artery bypass grafting (CABG) (13.6%), 
thoracic aortic surgery (13.5%), mitral valve surgery (2.1%) 
and tricuspid annuloplasty (1.6%). Median aortic cross-
clamp time was 60 [43–82] min and cardiopulmonary bypass 
time was 87 [65–116] min, 116.6±43.7 min (Table 2). 
Early outcomes
Overall 30-day mortality was 1.6%. Overall rate of stroke 
Table 1 Baseline characteristics (n=191) 
Characteristics Data
Male 92 (48.2)
Age 70.7±8.1
NYHA class
I 14 (7.4)
II 68 (36.2)
III 98 (52.1)
IV 8 (4.3)
Hypertension 105 (67.3)
Obesity 39 (20.5)
BMI 26.6±4.5
Diabetes 37 (22.0)
Dyslipidemia 75 (49.0)
AF 18 (13.7)
LVEF% 57.8±9.9
LVEF >50 157 (83.1)
LVEF 30–50 29 (15.3)
LVEF <30 3 (1.6)
Aortic valve regurgitation 1 (0.5)
Mixed aortic valve disease 83 (43.5)
Cerebrovascular disease 15 (8.3)
Renal insufficiency 50 (27.0)
Dialysis 1 (0.6)
CAD 44 (28.0)
Chronic lung disease 37 (20.1)
Redo 6 (3.1)
Urgent/emergent status 1 (0.6)
Logistic Euroscore, median (IQR) 5.8 (3.3–8.7)
Euroscore II, median (IQR) 1.6 (1–2.6)
Data present as n (%), mean ± SD, and median (IQR). NYHA, 
New York Heart Association; BMI, body mass index; LVEF, left 
ventricular ejection fraction; CAD, coronary artery disease; IQR, 
interquartile range.
Table 2 Operative data 
Variables Data
Full sternotomy 50 (26.2)
Ministernotomy 91 (47.6)
Right anterior minithoracotomy 50 (26.2)
Conversion to full sternotomy 2 (1.4)
Perceval 88 (46.1)
Intuity/Intuity Elite 103 (53.9)
Valve malpositioning 1 (0.5)
Associate procedures 61 (31.9)
CABG 26 (13.6)
Mitral valve surgery 4 (2.1)
Tricuspid valve surgery 3 (1.6)
Maze 6 (3.1)
Thoracic aorta surgery 25 (13.5)
Septal myectomy 4 (2.1)
Overall CPB time 87 [65–116]
Overall clamp time 60 [43–82]
Isolated AVR (min)
CPB time 80 [58–104]
Clamp time 55 [35.5-72]
Combined AVR (min)
CPB time 107 [79–141.5]
Clamp time 69 [54–96.3]
Data present as n (%) and median [IQR]. CABG, coronary 
artery bypass grafting; AVR, aortic valve replacement; IQR, 
interquartile range.
301Annals of cardiothoracic surgery, Vol 9, No 4 July 2020
© Annals of Cardiothoracic Surgery. All rights reserved. Ann Cardiothorac Surg 2020;9(4):298-304 | http://dx.doi.org/10.21037/acs-2020-surd-33
was 4.2% (isolated AVR 3.8% and combined procedure 
4.9%). Rate of AV block requiring pacemaker and atrial 
fibrillation were 7.9% and 31.9%, respectively. No cases 
of endocarditis, thromboembolism, myocardial infarction 
or structural valve deterioration were reported in the early 
phase. Median length of stay in the intensive care unit 
and hospital stay were 2 (IQR 1–4) and 12 [9–16] days, 
respectively. Other outcomes are reported in Table 3. 
Valve implanted
The Intuity valve was implanted in 53.9% of cases, whereas 
the Perceval was implanted in 46.1%. One case of Perceval 
valve malpositioning was reported, which required a second 
cross clamp and the same Perceval was repositioned. The 
most common size implanted for Perceval was large (36.3%), 
followed by medium (29.5%), extra large (26.1%) and small 
(7.9%). For Intuity, the most common size implanted was 
23 (32%), followed by 25 (25.2%), 27 (17.5%), 21 (13.6%) 
and 19 (11.6%) (Table 4). Overall rate of pacemaker 
implantation was 7.9% and was slightly higher in the Intuity 
group (9.7% vs. 5.7%, P=0.446). Overall rate of aortic 
regurgitation (AR) was 9.9% and similar between groups 
(Table 5). Rate of moderate and severe AR was 3.7%
Discussion
Our study demonstrated that in patients with BAV disease, 
AVR with either sutureless or rapid deployment valves is 
a safe procedure, associated with excellent outcomes and 
hemodynamic performances. Specifically, overall 30-day 
mortality was 1.6%, which reflected the predicted median 
Euroscore II. Furthermore, no cases of endocarditis, 
thromboembolism, myocardial infarction or structural valve 
deterioration were reported in the early phase. Interestingly, 
the majority of these procedures were performed through 
a minimally invasive approach, reinforcing the concept that 
SURD valves are not contraindicated in BAV. We reported 
only one case of valve migration (Perceval) which required a 
second cross clamp for repositioning the same valve. This is 
the largest case series study reporting outcomes of patients 
with BAV undergoing AVR with the Perceval or Intuity 
valve. These valves have been developed as an alternative 
to conventional, stented valves to reduce operative times 
and standardize the surgical procedure (3-7). Outcomes 
are excellent up to 10 years; however, these results focused 
Table 3 In-hospital outcomes
Variables Data
30-day mortality 3 (1.6)
Stroke 8 (4.2)
Low cardiac output –
Ventilatory support >72 h 4 (2.1)
New onset atrial fibrillation 53 (31.9)
New AV block requiring PM 15 (7.9)
Aortic regurgitation 19 (9.9)
Mild 12 (6.1)
Moderate 6 (3.3)
Severe 1 (0.6)
Bleeding requiring revision 6 (3.1)
AKI > stage 1 6 (3.1)
Dialysis –
Wound complications 7 (4.5)
ICU stay (days) 2 [1–4]
Hospital stay (days) 12 [9–16]
Data present as n (%) and median [IQR]. AV, atrio ventricular; 
PM, pacemaker; AKI, acute kidney disease; IQR, interquartile 
range.
Table 4 Valve prostheses: sizes and hemodynamics (n=191)
Peak gradient 
(mmHg),  
(mean ± SD) 
Mean gradient 
(mmHg),  
(mean ± SD)
Perceval 28.3±10.9 14.8±5.8
Small 35.4±8.8 18.5±3.9
Medium 32.6±9.2 16.7±4.9
Large 26.8±12.9 14.4±6.9
Extra-large 22.6±6.1 11.5±3.6
EDWARDS INTUITY/
INTUITY Elite
19.2±7 10.9±4.4
19 mm 23.9±8.4 14.1±5.2
21 mm 20.6±10.8 12.3±6.4
23 mm 18.4±5.5 10.4±3.4
25 mm 18.4±5.5 9.5±3.1
27 mm 17.1±4.8 9.7±3.4
302 Miceli et al. Sutureless & fast deployment valve in BAV
© Annals of Cardiothoracic Surgery. All rights reserved. Ann Cardiothorac Surg 2020;9(4):298-304 | http://dx.doi.org/10.21037/acs-2020-surd-33
mainly on patients presenting with tricuspid aortic valve 
(3,6,13). BAV has been considered a contraindication for 
the implantation of the SURD valve, as it is often associated 
with altered geometric root, sinus asymmetry, elliptic 
annulus and different commissural heights. In addition, 
some cases of migration and dislocation have been reported 
at follow-up, suggesting some words of caution in using 
these prostheses in BAV (11,12,14). An international 
expert consensus panel recommends the use of CT scan in 
defining the anatomical root geometry for evaluating aortic 
annulus, sinotubular junction and leaflet morphology (15). 
In the presence of BAV, experts recommend the use of 
SURD valves in type 1 Sievers classification as well as 
in some cases of type 2 when the two commissures have 
approximately the same height. Conversely, the absence of 
raphe (type 0) is considered an absolute contraindication, 
because of its anatomy related to asymmetric height of 
commissures, unequal width of the sinuses of Valsalva and 
180° orientation of the coronary ostia. 
Nguyen et al. reported the first case series of 25 type 
I BAV patients and aortic stenosis receiving the Perceval 
valve (8). Interestingly, neither migration nor structural 
damage occurred at follow-up and only 3 patients had 
trace of AR. The key points for a perfect sealing of SURD 
valves are the symmetry of the aortic annulus and the 
equality of the heights of the leaflet commissures. Nguyen 
et al. suggested recreating the 3 nadir points positioned at 
120 degrees as it is in a tricuspid valve. However, this 
technique is suitable only in type I BAV when 3 equal 
commissures and sinus of Valsalva are present. In all 
other cases, a commissural plication is required to restore 
the circularity of the aortic annulus, especially when 
commissures are placed at different heights (10). Based 
on this technical consideration, Durdu et al. reported 13 
successful cases of AVR through minithoracotomy with 
Perceval in BAV, of whom 4 had type 0 and 2 type 2 BAV (9). 
In addition to the intercommissural triangle plication for 
annular remodeling, authors recommended a thorough 
decalcification of the aortic annulus as it restores its elasticity 
and adaptability to the implanted prosthesis. We finally add 
that the correct sizing is essential in avoiding postoperative 
AR and pacemaker implantation. The choice of a smaller 
valve may be associated with paravalvular leakage for the 
Intuity valve and central AR for the Perceval. Conversely, a 
larger valve might be associated with increased pacemaker 
implantation rate for both valves and potential hemodynamic 
turbulence in the case of the Perceval valve. 
Rate of postoperative stroke was higher compared to 
other studies involving SURD and that deserves some 
potential explanation. BAV is often heavily calcified and 
its debridement to restore the annular circularity may 
have contributed this result. Furthermore, one patient 
had a previous stroke. Finally, this rate was higher in 
combined procedures (3.8% vs. 4.9%). It is well known 
Table 5 Rate of pacemaker implantation and aortic regurgitation
Variables
Pacemaker 
implantation
Overall AR Mild AR Moderate AR Severe AR
Perceval (n=88) 5 (5.7%) 8 (9.1%) 6 (6.8%) 2 (2.3%) –
Small (n=7) 0 1 (1.1%) 1 (1.1%) – –
Medium (n=26) 1 (1.1%) 3 (3.4%) 2 (2.3%) 1 (1.1%) –
Large (n=32) 3 (3.4%) 4 (4.5%) 3 (3.4%) 1 (1.1%) –
Extra-large (n=23) 1 (1.1%) 1 (1.1%) – – –
EDWARS INTUITY/INTUITY Elite (n=103) 10 (9.7%) 11 (10.7%) 6 (5.8%) 4 (3.9%) 1 (1.0%)
19 mm (n=12) 0 5 (4.9%) 3 (2.9%) 2 (1.9%) –
21 mm (n=14) 2 (1.9%) 0 – – –
23 mm (n=33) 1 (1.0%) 1 (1.0%) 1 (1.0%) – –
25 mm (n=26) 5 (4.9%) 3 (2.9%) 1 (1.0%) 1 (1.0%) 1 (1.0%)
27 mm (n=18) 2 (1.9%) 2 (1.9%) 1 (1.0%) 1 (1.0%) –
AR, aortic regurgitation.
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that combined procedures are associated with a higher 
complication risk (16,17).
The rate of significant postoperative AR was 3.7%. This 
data is in the line with others. However, when compared 
with the overall population of SURD registry, we found 2.5 
times the increased risk of postoperative AR, highlighting 
the complexity of BAV anatomy and the importance of 
restoring the annular circumference for a perfect result (5). 
The incidence of pacemaker (PMK) implantation 
was 7.9% (15 patients). Several mechanisms may be 
associated with PMK implantation, the most common 
contributing factor being mechanical trauma related to 
decalcification and the expansion of both valves at the 
level of left ventricular outflow tract. However, extensive 
debridement of the aortic annulus and center timing policy 
for PMK implantation may have also contributed (18). 
Finally, the absolute number of pacemaker implantations 
was low, therefore we were not able to evaluate a potential 
improvement of this rate over the years. 
This study presents several limitations. First, it is based 
on the retrospective analysis of the SURD international 
registry. Therefore, we were unable to account for 
influence of any residual unmeasured factors that could 
affect the adverse outcomes. Second, our database does 
not account for the Sievers classification and it is not 
possible to investigate between BAV type and AR. Then, 
our database was not able to distinguish paravalvular leak 
or central regurgitation. Finally, no follow-up is available 
and therefore we do not know about any potential cases of 
dislocation/migration.
In conclusion, BAV itself is not a contraindication for 
implantation of SURD valve. However, a word of caution 
is required. Even though we dealt with any type of BAV, 
AVR with SURD in type 0 BAV is technically demanding. 
Detailed information of aortic root geometry as well 
as the knowledge of some technical considerations—
decalcification, sizing, and annular remodeling—are 
mandatory for a good outcome. 
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